Alpha 2.0
Login Register
» Authors » D Franceschini

D Franceschini

Explore the profile of D Franceschini including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 65
Citations 549
Followers 0
Related Specialties
Oncology
Genetics
Radiology
Top 10 Co-Authors
P Franceschini
A Guala
M Scorsetti
C Franzese
D Licata
G Di Cara
P Giusti
F Signorile
M P Vardeu
L Livi
Published In
Am J Med Genet
Radiother Oncol
Clin Oncol (R Coll Radiol)
FASEB J
Restor Neurol Neurosci
Affiliations
Soon will be listed here.
Recent Articles
1.
Prospective phase II trial on ablative stereotactic body radiation therapy (SBRT) for medically inoperable thoracic nodes metastases
Franceschini D, Teriaca M, Mancosu P, Bertolini A, Lo Faro L, Spoto R, et al.
Radiother Oncol . 2024 May; 197:110335. PMID: 38772477
Background: Oligometastases in mediastinal nodes are increasingly prevalent, posing challenges for treatment with stereotactic body radiotherapy (SBRT) due to proximity to organs at risk (OARs). We report the results of...
2.
Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer
Franceschini D, Franzese C, Comito T, Ilieva M, Spoto R, Marzo A, et al.
Radiother Oncol . 2024 Mar; 195:110240. PMID: 38522597
Background And Purpose: To report mature results for local control and survival in oligometastatic (OM) breast cancer patients treated with stereotactic body radiotherapy (SBRT) on lung and/or liver lesions in...
3.
Adjuvant Hypofractionated Whole Breast Irradiation (WBI) vs. Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5Years Update of the HYPAB Trial
Lo Faro L, Fogliata A, Franceschini D, Spoto R, Dominici L, Bertolini A, et al.
Clin Breast Cancer . 2024 Jan; 24(3):253-260. PMID: 38220538
Therapeutical strategies in breast cancer are continuously updating. Recent researches assessed the possibility of irradiating only the surgical bed in selected patients (Partial Breast Irradiation, PBI). In 2014 we designed...
4.
Oligometastatic sarcoma treated with Curative intent Ablative Radiotherapy (OSCAR): A multicenter study on behalf of AIRO (Italian association of Radiotherapy and clinical Oncology)
Franceschini D, Greto D, Dicuonzo S, Navarria F, Federico M, La Vecchia M, et al.
Radiother Oncol . 2024 Jan; 191:110078. PMID: 38163485
Background And Purpose: Stereotactic Ablative Radiotherapy (SABR) is emerging as a valid alternative to surgery in the oligometastatic setting in soft tissue sarcomas (STS), although robust data are lacking. The...
5.
Oligometastatic Prostate Cancer Treated with Stereotactic Body Radiation Therapy: The Role of Three-Dimensional Tumour Volume in Patient Survival
Franzese C, Lucchini R, Roghi M, Badalamenti M, Baldaccini D, Comito T, et al.
Clin Oncol (R Coll Radiol) . 2023 Sep; 35(12):e649-e656. PMID: 37775459
Aims: The definition of oligometastatic prostate cancer (OPCa) is currently based solely on the maximum number of detectable metastases, as there are no validated biomarkers available. The aim of this...
6.
The pattern of failure after Stereotactic Radiation Therapy (SRT) for oligo-metastases: predictive factors for poly-progression
Franceschini D, Cozzi L, Vernier V, Marzo A, Marini B, Stefanini S, et al.
J Cancer Res Clin Oncol . 2022 Nov; 149(8):5173-5179. PMID: 36357737
Purpose: Patients with oligo-metastatic disease (OMD) can be safely treated with Stereotactic Radiation Therapy (SRT). Further disease progression is common in these patients. In most cases, patients relapse again with...
7.
Risk-group Classification by Recursive Partitioning Analysis of Patients Affected by Oligometastatic Renal Cancer Treated with Stereotactic Radiotherapy
Franzese C, Navarria P, Bellu L, Marzo M, Clerici E, Badalamenti M, et al.
Clin Oncol (R Coll Radiol) . 2022 Jan; 34(6):379-385. PMID: 35027286
Aims: Due to the absence of consensus on metastases-directed treatment in kidney cancer, we conducted an analysis of patients treated with stereotactic radiotherapy (SRT) on cranial or extracranial metastases to...
8.
A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study
Nicosia L, Franceschini D, Perrone-Congedi F, Casamassima F, Gerardi M, Rigo M, et al.
Radiother Oncol . 2021 Nov; 166:92-99. PMID: 34748855
Introduction: Stereotactic ablative radiotherapy (SABR) has been shown to increase survival in oligometastatic disease, but local control of colorectal metastases remains poor. We aimed to identify potential predictive factors of...
9.
Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost
Franceschini D, Fogliata A, Spoto R, Dominici L, Lo Faro L, Franzese C, et al.
Radiother Oncol . 2021 Sep; 164:50-56. PMID: 34537289
Purpose: to report toxicity and cosmetic outcome with a median follow-up of 6 years of a phase II trial of hypofractionated radiotherapy with volumetric modulated arc therapy (VMAT) and simultaneous...
10.
Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs
Franceschini D, Rossi S, Loi M, Chiola I, Piccoli F, Lutman F, et al.
Expert Rev Anticancer Ther . 2020 Aug; 20(9):743-753. PMID: 32755244
Introduction: Patients treated with third-generation EGFR TKIs will develop resistance to treatment at a certain point. Early detection of resistance occurrence could allow more options for treatment. Areas Covered: We...